SPS 4251

Drug Profile

SPS 4251

Alternative Names: PAP-1; SPS-4251

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Airmid
  • Developer Circassia
  • Class Antipsoriatics
  • Mechanism of Action Immunosuppressants; Kv1.3 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (Topical, Ointment)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom (Topical, Ointment)
  • 16 Jul 2013 Circassia completes a phase Ib trial in Plaque psoriasis in Germany (NCT01743118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top